Hailey 24 Fe Kit
Product Images NDC 68462-731

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Hailey 24 Fe (NDC 68462-731). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glenmark Pharmaceuticals Inc., Usa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1

A forest plot comparing various studies on combined oral contraceptive (COC) use versus never use, showing odds ratios (OR), relative risks (RR), and hazard ratios (HR) with confidence intervals. The plot lists studies from 2002 to 2017, including NICHD Women’s Care, French E3N cohort, Shanghai Women's Health, Nurses' Health, Oxford Family Planning, and Danish Sex Hormone Register studies. The horizontal axis ranges from -1.50 to 2.00, with a vertical reference line at 1.00 aligning with the point estimates and confidence intervals.*

FDA Label Image

Carton

Hailey 24 Fe kit containing norethindrone acetate and ethinyl estradiol tablets USP, and ferrous fumarate tablets. The label states a strength of 1 mg/20 mcg for the hormonal tablets. The package includes 3 blisters of 28 tablets each providing 24 days of active therapy. The labeler is Glenmark Pharmaceuticals Inc., USA. Additional details include storage instructions, pharmacist dispensing information, and a note that the package is not child resistant.*

FDA Label Image

Chart

A vertical arrow chart titled 'Fewer Pregnancies' at the top and 'More Pregnancies' at the bottom, illustrating the effectiveness of different birth control methods. It lists methods associated with fewer pregnancies per 100 women per year, such as implants, injections, intrauterine devices, and sterilization, progressing down through birth control pills, skin patch, and vaginal ring with hormones, then condoms and diaphragm, followed by no sex during fertile days, spermicide, and withdrawal, ending with no birth control linked to the most pregnancies.*

FDA Label Image

Structure 1.jpg (Image 01)

Chemical structure diagram of the active ingredient ethinyl estradiol in Hailey 24 Fe, a human prescription drug kit by Glenmark Pharmaceuticals Inc., USA.*

FDA Label Image

Structure 2.jpg (Image 02)

Chemical structure of norethindrone acetate, an active ingredient in Hailey 24 Fe. The diagram depicts the molecular arrangement including rings and functional groups associated with norethindrone acetate.*

FDA Label Image

Figure 1.jpg (Image 03)

A pharmacokinetic curve showing norethindrone concentration (pg/mL) over time (hours) with two data series labeled Day 1 and Day 24. The graph plots drug concentration decline from peak levels over a 60-hour period, comparing early and later time points.*

FDA Label Image

Figure 2.jpg (Image 04)

A pharmacokinetic curve illustrating the plasma concentration of ethinyl estradiol (pg/mL) over time (hours) following dosing on Day 1 and Day 24. The graph shows a peak in concentration shortly after dosing, followed by a gradual decline over 60 hours, with separate traces for the first and the twenty-fourth day of administration.*

FDA Label Image

Patientcard.jpg (Image 06)

An instructional diagram showing the pill-taking schedule for Hailey 24 Fe oral contraceptive kit. It lays out a 4-week calendar with rows labeled Week 1 through Week 4 and columns for each day of the week starting Sunday. Arrows indicate taking the pills from left to right in each week. Instructions guide Sunday starters to start on Sunday and Day-1 starters to place the day label strip starting from the first day of their period.*

FDA Label Image

Sticker.jpg (Image 07)

FDA Label Image

Laminate

Packaging label for Hailey 24 Fe (norethindrone acetate and ethinyl estradiol, and ferrous fumarate) tablets USP 1 mg/20 mcg. Kit contains 1 blister of 28 tablets providing 24 days of active therapy. Manufactured by Glenmark Pharmaceuticals Limited and labeled by Glenmark Pharmaceuticals Inc., USA. Includes NDC 68462-731-84 and storage, dosage, and dispensing information.*

FDA Label Image

Logo

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.